Hinge Health’s Earnings Call Signals Profitable Growth

Hinge Health, Inc. Class A ((HNGE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Hinge Health, Inc. delivered an upbeat earnings call that underscored strong momentum across its business. Management highlighted a powerful combination of faster revenue growth, expanding margins, and rising free cash flow, while acknowledging some near-term headwinds around device costs, sales seasonality, and modest early revenue from its new migraine program.

Revenue Beat and Strong Top-Line Growth

Hinge Health opened the quarter with a standout revenue beat that underscored the strength of demand for its digital musculoskeletal solutions. Q1 revenue reached $182 million, up 47% year over year from $124 million and running well ahead of the company’s prior guidance range of $171 million to $173 million.

Calculated Billings Expansion

Behind the revenue surge, calculated billings continued to climb at an even faster clip, signaling robust future revenue visibility. Over the last twelve months, calculated billings hit $770 million, a 52% jump from $507 million in the same period a year earlier, pointing to sustained client uptake and multi-year contract depth.

Robust Margin and Profitability Improvement

Profitability took a major step change higher as Hinge Health combined revenue growth with tight cost control. Gross margin expanded to 85%, up 400 basis points year on year, while operating margin rose to 25% from 12% and operating income reached $46 million, well ahead of guidance for $30 million to $32 million.

Free Cash Flow and Balance Sheet Strength

The company converted those profits into cash at a much faster pace, signaling improving financial quality. Free cash flow climbed to $42 million, roughly ten times the prior-year level, lifting the free cash flow margin to 23% and helping boost cash and equivalents to a healthy $407 million at quarter end.

Raised Full-Year Guidance

On the back of its strong start, Hinge Health raised expectations for the full year, sending a clear signal of confidence in the trajectory of the business. The company now forecasts 2026 revenue of $798 million to $804 million, implying about 36% growth at the midpoint, alongside operating income of $205 million to $215 million and an operating margin of roughly 26%.

Product Expansion: Migraine Program and FDA Clearance

A major strategic highlight was the launch of a migraine care program, powered by the Enso device receiving 510(k) clearance from regulators. In trials, more than half of participants saw pain fall from severe or moderate to mild or none, and users were nearly twice as likely to reduce pain versus placebo, helping the program quickly land over 125 clients and more than 2 million eligible lives.

Commercial Momentum and Network Growth

Commercial traction remains a core growth engine, with management calling out a pipeline significantly stronger than a year ago. The small and mid-sized business channel more than doubled its pipeline, Hinge Select expanded to 4,100 provider locations with broader distribution through a national pharmacy benefits manager and major health plans, and about 80% of contracted lives now sit on engagement-based pricing.

Capital Deployment and Share Count Reduction

Hinge Health is also leaning into shareholder returns as its balance sheet strengthens. The company repurchased $105 million of stock during the quarter, buying back 2.5 million shares and reducing diluted weighted-average shares to 82.4 million, which helped drive diluted net income per share to $0.45.

Limited Near-Term Revenue from Migraine

Despite the early commercial enthusiasm for its migraine launch, management urged investors to temper near-term revenue expectations from this line of business. The company expects minimal top-line contribution from migraine in 2026, with a more meaningful financial impact not anticipated until 2027 as adoption and usage scale.

Seasonal Sales Cycle Concentration

Hinge Health also reminded investors that its sales model remains seasonally skewed, which can inject volatility into quarterly results. Historically, most new client wins close in the back half of the year, concentrating revenue realization around that period and creating timing risk if deal cycles slip.

Decision to Sit Out CMS ACCESS Program

In a notable strategic choice, the company opted not to pursue participation in a federal access initiative targeting certain populations. Management cited concerns over clinical oversight and program design, suggesting the trade-off between scale and quality did not meet its standards, even though it potentially delays expansion into broader government-covered markets.

Device Deployment Cost Pressure

The rapid scaling of Enso devices, while central to product strategy, is introducing some cost pressure that investors should watch. Device distributions roughly doubled in 2025 versus 2024 and are planned to grow about 40% in 2026, which can weigh on cost of goods and gross margin even as efficiencies in the care team partially offset the impact.

Legacy Pricing Mix Remains

Pricing strategy is still in transition, leaving some upside on the table in the near term. Around 20% of contracted lives remain on older subscription-style pricing, and management expects the shift to engagement-based pricing for all clients to be gradual, limiting average revenue per user expansion until the mix fully normalizes.

Temporary Hiring Slowdown and Future Costs

The company’s margin gains were aided by a deliberate slowdown in hiring, but management signaled that this is not permanent. As Hinge Health moves to “catch up” on staffing later in the year to support growth and new programs, operating expenses are likely to rise, which could moderate the pace of future margin expansion.

Forward-Looking Guidance and Outlook

Looking ahead, the company’s guidance frames a story of continued high growth with disciplined profitability, even as new investments ramp. Management expects Q2 revenue in a wide band of $104 million to $196 million with operating margins around 25%, while for the full year roughly half of the guidance raise stems from higher yield per client and half from growth in covered lives.

Hinge Health’s latest earnings call painted a picture of a high-growth digital health company maturing quickly into a profitable, cash-generating platform. While investors must weigh device-related costs, sales seasonality, and measured monetization of migraine, the overarching narrative is one of accelerating scale, rising margins, and increasing confidence in the company’s long-term financial and strategic trajectory.